查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1586208

头孢菌素药物市场：按头孢菌素的世代、药物管理、处方类型和应用划分 - 全球预测 2025-2030

Cephalosporin Drugs Market by Generation of Cephalosporin (Fifth-Generation, First-Generation, Fourth-Generation), Drug Administration (Injection, Oral), Prescription Type, Application - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 189 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年头孢菌素类药物市值为113.7亿美元，预计2024年将达到121.1亿美元，复合年增长率为6.66%，预计2030年将达到178.6亿美元。

头孢菌素药物是一类主要的 β-内酰胺抗生素，对于治疗多种细菌感染疾病至关重要。该系列跨越多代，每代都具有不同的抗菌特性和临床应用。这些药物对于抵抗呼吸道感染疾病、皮肤感染疾病和尿道感染感染疾病至关重要，因此在医院和门诊环境中都至关重要。细菌感染疾病流行率的上升和抗生素抗药性菌株的不断出现凸显了对头孢菌素市场的需求。新兴医疗保健领域不断增长的需求以及手术预防中程序采用的增加证实了头孢菌素的重要应用范围。影响市场的关键发展因素包括药物研发的进步、下一代头孢菌素的强大管道以及新兴国家医疗保健支出的增加。开发针对多重抗药性细菌的新製剂以及扩大头孢菌素在兽药中的使用存在潜在机会，反映了医疗必要性和市场需求的融合。然而，该市场面临严格的法律规范、潜在的副作用以及头孢菌素抗药性细菌增加等限制，需要市场相关人员谨慎引导。高研发成本和其他抗生素类别的竞争等竞争因素也成为扩张的障碍。业务成长的创新领域包括提高药物疗效，同时最大限度地减少副作用，以及透过开发新化合物和联合治疗来解决抗药性细菌问题。注重製药公司和学术机构之间的合作可以在这些领域取得突破。竞争激烈的头孢菌素市场需要在研发和地理扩张方面进行策略性投资，以开拓未满足的临床需求，特别是在新兴市场。总体而言，市场的性质需要敏捷性和创新，以适应全球医疗保健优先事项和抗生素抗药性的演变。

主要市场统计
基准年[2023] 113.7亿美元
预测年份 [2024] 121.1亿美元
预测年份 [2030] 178.6亿美元
复合年增长率（%） 6.66%

市场动态：揭示快速发展的头孢菌素药物市场的关键市场洞察

供需的动态交互作用正在改变头孢菌素药品市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，并了解消费行为及其对製造成本的影响，并更清楚地了解对采购趋势的影响。

  • 市场驱动因素
    • 皮肤和尿道结石等细菌感染病例增加
    • 持续关注研究、开发和临床试验
    • 联合治疗的普及
  • 市场限制因素
    • 与头孢菌素相关的副作用
  • 市场机会
    • 药企、协会加大投入，加速抗生素药物研发
    • 有利于抗生素药物的政府法规修正案
  • 市场挑战
    • 由于人们意识有限，农村和偏远地区的供需失衡

波特五力：驾驭头孢菌素药品市场的策略工具

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解头孢菌素类药物市场的外部影响

外部宏观环境因素在塑造头孢菌素药品市场的绩效动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析 了解头孢类药物市场竞争格局

对头孢菌素药品市场的详细市场占有率分析可以对供应商的绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵头孢菌素药品市场供应商的绩效评估

FPNV 定位矩阵是评估头孢菌素药品市场供应商的重要工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商，从而做出符合其目标的明智决策。这四个象限使您能够清晰、准确地划分供应商，以确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析和建议绘製头孢菌素药物市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，头孢菌素药品市场的策略分析至关重要。透过考虑关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机，并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：对当前市场环境的详细审查、主要企业的广泛资料、对其在市场中的影响力和整体影响力的评估。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 皮肤感染疾病和尿道感染等细菌感染疾病增加
      • 持续关注研发和临床试验
      • 联合治疗的广泛应用
    • 抑制因素
      • 与头孢菌素相关的副作用
    • 机会
      • 药厂和协会加大投入，加速抗生素研发
      • 支持抗生素药物的政府法规修正案
    • 任务
      • 农村和边远地区公众认知度低，供需失衡
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章 头孢药品市场 头孢世代

  • 第五代
  • 第一代
  • 第四代
  • 第二代
  • 第三代

第七章 药品监督管理部门的头孢类药品市场

  • 注射
  • 口服

第八章 头孢类药物市场（依处方笺型）

  • 非处方药
  • 处方药

第九章 头孢菌素药品市场：依应用分类

  • 耳部感染疾病
  • 呼吸道感染疾病
  • 皮肤感染疾病
  • 尿道感染

第十章 美洲头孢菌素药品市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十一章亚太地区头孢类药物市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十二章 欧洲、中东和非洲头孢类药物市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十三章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • Abbott Laboratories
  • AbbVie Inc.
  • Aristo Pharmaceuticals Ltd.
  • AstraZeneca PLC
  • Baxter International, Inc.
  • Bayer AG
  • Covalent Laboratories Private Limited
  • Eli Lilly and Company
  • GlaxoSmithKline Plc
  • Lupin Limited
  • Macleods Pharmaceuticals Ltd
  • Novartis International AG
  • Shionogi & Co., Ltd.
  • Sun Pharmaceutical Industries Ltd.
  • Taj Pharmaceuticals Limited
  • Teva Pharmaceutical Industries Ltd.
Product Code: MRR-433AB1DC28F3

The Cephalosporin Drugs Market was valued at USD 11.37 billion in 2023, expected to reach USD 12.11 billion in 2024, and is projected to grow at a CAGR of 6.66%, to USD 17.86 billion by 2030.

Cephalosporin drugs, a major class of beta-lactam antibiotics, are pivotal in treating a broad spectrum of bacterial infections. Their scope spans multiple generations, each characterized by distinct antibacterial properties and clinical applications. These drugs are vital in combating infections such as respiratory tract infections, skin infections, and urinary tract infections, making them essential in both hospital and ambulatory settings. The cephalosporin market's necessity is underscored by the rising prevalence of bacterial infections and the continual emergence of antibiotic-resistant strains. The increasing demand from emerging healthcare sectors and the growing procedural adoption in surgical prophylaxis underscore their vital application scope. Key growth factors influencing the market include advancing pharmaceutical R&D, a robust pipeline for next-generation cephalosporins, and rising healthcare spending in developing regions. Potential opportunities lie in developing novel formulations targeting multi-drug resistant bacteria and expanding cephalosporin applications in veterinary medicine, reflecting a convergence between medical necessity and market demand. However, the market faces limitations including stringent regulatory frameworks, potential adverse effects, and the increasing prevalence of cephalosporin-resistant bacteria, necessitating careful navigation by market players. Challenging factors such as the high cost of R&D and competition from other antibiotic classes also pose barriers to expansive growth. For business growth, innovation areas include enhancing drug efficacy while minimizing side effects and addressing resistance through novel compound development and combination therapies. An emphasis on collaborations among pharmaceutical companies and academic institutions can generate breakthroughs in these areas. The cephalosporin market is competitive, necessitating strategic investments in R&D and geographical expansion to tap into unmet clinical needs, particularly in emerging markets. Overall, the nature of the market demands agility and innovations that align with global healthcare priorities and the evolving landscape of antibiotic resistance.

KEY MARKET STATISTICS
Base Year [2023] USD 11.37 billion
Estimated Year [2024] USD 12.11 billion
Forecast Year [2030] USD 17.86 billion
CAGR (%) 6.66%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Cephalosporin Drugs Market

The Cephalosporin Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Growing cases of bacterial infection such as skin and UTIs
    • Continuous focus on R&D and clinical trials
    • Widespread application of a combination therapy
  • Market Restraints
    • Side effects related to cephalosporins drugs
  • Market Opportunities
    • Increasing investment by pharmaceutical companies & associations to boost the antibiotic drug development
    • Revised government regulation in favor of antibiotic drugs
  • Market Challenges
    • Limited consciousness among the people and unbalanced demand & supply in rural or remote areas

Porter's Five Forces: A Strategic Tool for Navigating the Cephalosporin Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Cephalosporin Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Cephalosporin Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Cephalosporin Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Cephalosporin Drugs Market

A detailed market share analysis in the Cephalosporin Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Cephalosporin Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Cephalosporin Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Cephalosporin Drugs Market

A strategic analysis of the Cephalosporin Drugs Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Cephalosporin Drugs Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AbbVie Inc., Aristo Pharmaceuticals Ltd., AstraZeneca PLC, Baxter International, Inc., Bayer AG, Covalent Laboratories Private Limited, Eli Lilly and Company, GlaxoSmithKline Plc, Lupin Limited, Macleods Pharmaceuticals Ltd, Novartis International AG, Shionogi & Co., Ltd., Sun Pharmaceutical Industries Ltd., Taj Pharmaceuticals Limited, and Teva Pharmaceutical Industries Ltd..

Market Segmentation & Coverage

This research report categorizes the Cephalosporin Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Generation of Cephalosporin, market is studied across Fifth-Generation, First-Generation, Fourth-Generation, Second-Generation, and Third-Generation.
  • Based on Drug Administration, market is studied across Injection and Oral.
  • Based on Prescription Type, market is studied across OTC Drugs and Prescription Drugs.
  • Based on Application, market is studied across Ear Infection, Respiratory Tract Infection, Skin Infection, and Urinary Tract Infection.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing cases of bacterial infection such as skin and UTIs
      • 5.1.1.2. Continuous focus on R&D and clinical trials
      • 5.1.1.3. Widespread application of a combination therapy
    • 5.1.2. Restraints
      • 5.1.2.1. Side effects related to cephalosporins drugs
    • 5.1.3. Opportunities
      • 5.1.3.1. Increasing investment by pharmaceutical companies & associations to boost the antibiotic drug development
      • 5.1.3.2. Revised government regulation in favor of antibiotic drugs
    • 5.1.4. Challenges
      • 5.1.4.1. Limited consciousness among the people and unbalanced demand & supply in rural or remote areas
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Cephalosporin Drugs Market, by Generation of Cephalosporin

  • 6.1. Introduction
  • 6.2. Fifth-Generation
  • 6.3. First-Generation
  • 6.4. Fourth-Generation
  • 6.5. Second-Generation
  • 6.6. Third-Generation

7. Cephalosporin Drugs Market, by Drug Administration

  • 7.1. Introduction
  • 7.2. Injection
  • 7.3. Oral

8. Cephalosporin Drugs Market, by Prescription Type

  • 8.1. Introduction
  • 8.2. OTC Drugs
  • 8.3. Prescription Drugs

9. Cephalosporin Drugs Market, by Application

  • 9.1. Introduction
  • 9.2. Ear Infection
  • 9.3. Respiratory Tract Infection
  • 9.4. Skin Infection
  • 9.5. Urinary Tract Infection

10. Americas Cephalosporin Drugs Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Cephalosporin Drugs Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Cephalosporin Drugs Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. AbbVie Inc.
  • 3. Aristo Pharmaceuticals Ltd.
  • 4. AstraZeneca PLC
  • 5. Baxter International, Inc.
  • 6. Bayer AG
  • 7. Covalent Laboratories Private Limited
  • 8. Eli Lilly and Company
  • 9. GlaxoSmithKline Plc
  • 10. Lupin Limited
  • 11. Macleods Pharmaceuticals Ltd
  • 12. Novartis International AG
  • 13. Shionogi & Co., Ltd.
  • 14. Sun Pharmaceutical Industries Ltd.
  • 15. Taj Pharmaceuticals Limited
  • 16. Teva Pharmaceutical Industries Ltd.

LIST OF FIGURES

  • FIGURE 1. CEPHALOSPORIN DRUGS MARKET RESEARCH PROCESS
  • FIGURE 2. CEPHALOSPORIN DRUGS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY GENERATION OF CEPHALOSPORIN, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY GENERATION OF CEPHALOSPORIN, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS CEPHALOSPORIN DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS CEPHALOSPORIN DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES CEPHALOSPORIN DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES CEPHALOSPORIN DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC CEPHALOSPORIN DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC CEPHALOSPORIN DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA CEPHALOSPORIN DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA CEPHALOSPORIN DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. CEPHALOSPORIN DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. CEPHALOSPORIN DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. CEPHALOSPORIN DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. CEPHALOSPORIN DRUGS MARKET DYNAMICS
  • TABLE 7. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY GENERATION OF CEPHALOSPORIN, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY FIFTH-GENERATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY FIRST-GENERATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY FOURTH-GENERATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY SECOND-GENERATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY THIRD-GENERATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY INJECTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY OTC DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY PRESCRIPTION DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY EAR INFECTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY RESPIRATORY TRACT INFECTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY SKIN INFECTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY URINARY TRACT INFECTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS CEPHALOSPORIN DRUGS MARKET SIZE, BY GENERATION OF CEPHALOSPORIN, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS CEPHALOSPORIN DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS CEPHALOSPORIN DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 29. ARGENTINA CEPHALOSPORIN DRUGS MARKET SIZE, BY GENERATION OF CEPHALOSPORIN, 2018-2030 (USD MILLION)
  • TABLE 30. ARGENTINA CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 31. ARGENTINA CEPHALOSPORIN DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 32. ARGENTINA CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 33. BRAZIL CEPHALOSPORIN DRUGS MARKET SIZE, BY GENERATION OF CEPHALOSPORIN, 2018-2030 (USD MILLION)
  • TABLE 34. BRAZIL CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 35. BRAZIL CEPHALOSPORIN DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 36. BRAZIL CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 37. CANADA CEPHALOSPORIN DRUGS MARKET SIZE, BY GENERATION OF CEPHALOSPORIN, 2018-2030 (USD MILLION)
  • TABLE 38. CANADA CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 39. CANADA CEPHALOSPORIN DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 40. CANADA CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 41. MEXICO CEPHALOSPORIN DRUGS MARKET SIZE, BY GENERATION OF CEPHALOSPORIN, 2018-2030 (USD MILLION)
  • TABLE 42. MEXICO CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 43. MEXICO CEPHALOSPORIN DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. MEXICO CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 45. UNITED STATES CEPHALOSPORIN DRUGS MARKET SIZE, BY GENERATION OF CEPHALOSPORIN, 2018-2030 (USD MILLION)
  • TABLE 46. UNITED STATES CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 47. UNITED STATES CEPHALOSPORIN DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. UNITED STATES CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 49. UNITED STATES CEPHALOSPORIN DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 50. ASIA-PACIFIC CEPHALOSPORIN DRUGS MARKET SIZE, BY GENERATION OF CEPHALOSPORIN, 2018-2030 (USD MILLION)
  • TABLE 51. ASIA-PACIFIC CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 52. ASIA-PACIFIC CEPHALOSPORIN DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. ASIA-PACIFIC CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 54. ASIA-PACIFIC CEPHALOSPORIN DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 55. AUSTRALIA CEPHALOSPORIN DRUGS MARKET SIZE, BY GENERATION OF CEPHALOSPORIN, 2018-2030 (USD MILLION)
  • TABLE 56. AUSTRALIA CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 57. AUSTRALIA CEPHALOSPORIN DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. AUSTRALIA CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 59. CHINA CEPHALOSPORIN DRUGS MARKET SIZE, BY GENERATION OF CEPHALOSPORIN, 2018-2030 (USD MILLION)
  • TABLE 60. CHINA CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 61. CHINA CEPHALOSPORIN DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. CHINA CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 63. INDIA CEPHALOSPORIN DRUGS MARKET SIZE, BY GENERATION OF CEPHALOSPORIN, 2018-2030 (USD MILLION)
  • TABLE 64. INDIA CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 65. INDIA CEPHALOSPORIN DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. INDIA CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 67. INDONESIA CEPHALOSPORIN DRUGS MARKET SIZE, BY GENERATION OF CEPHALOSPORIN, 2018-2030 (USD MILLION)
  • TABLE 68. INDONESIA CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 69. INDONESIA CEPHALOSPORIN DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. INDONESIA CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 71. JAPAN CEPHALOSPORIN DRUGS MARKET SIZE, BY GENERATION OF CEPHALOSPORIN, 2018-2030 (USD MILLION)
  • TABLE 72. JAPAN CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 73. JAPAN CEPHALOSPORIN DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. JAPAN CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 75. MALAYSIA CEPHALOSPORIN DRUGS MARKET SIZE, BY GENERATION OF CEPHALOSPORIN, 2018-2030 (USD MILLION)
  • TABLE 76. MALAYSIA CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 77. MALAYSIA CEPHALOSPORIN DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. MALAYSIA CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 79. PHILIPPINES CEPHALOSPORIN DRUGS MARKET SIZE, BY GENERATION OF CEPHALOSPORIN, 2018-2030 (USD MILLION)
  • TABLE 80. PHILIPPINES CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 81. PHILIPPINES CEPHALOSPORIN DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. PHILIPPINES CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 83. SINGAPORE CEPHALOSPORIN DRUGS MARKET SIZE, BY GENERATION OF CEPHALOSPORIN, 2018-2030 (USD MILLION)
  • TABLE 84. SINGAPORE CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 85. SINGAPORE CEPHALOSPORIN DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. SINGAPORE CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 87. SOUTH KOREA CEPHALOSPORIN DRUGS MARKET SIZE, BY GENERATION OF CEPHALOSPORIN, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH KOREA CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 89. SOUTH KOREA CEPHALOSPORIN DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. SOUTH KOREA CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 91. TAIWAN CEPHALOSPORIN DRUGS MARKET SIZE, BY GENERATION OF CEPHALOSPORIN, 2018-2030 (USD MILLION)
  • TABLE 92. TAIWAN CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 93. TAIWAN CEPHALOSPORIN DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. TAIWAN CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 95. THAILAND CEPHALOSPORIN DRUGS MARKET SIZE, BY GENERATION OF CEPHALOSPORIN, 2018-2030 (USD MILLION)
  • TABLE 96. THAILAND CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 97. THAILAND CEPHALOSPORIN DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. THAILAND CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 99. VIETNAM CEPHALOSPORIN DRUGS MARKET SIZE, BY GENERATION OF CEPHALOSPORIN, 2018-2030 (USD MILLION)
  • TABLE 100. VIETNAM CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 101. VIETNAM CEPHALOSPORIN DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. VIETNAM CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA CEPHALOSPORIN DRUGS MARKET SIZE, BY GENERATION OF CEPHALOSPORIN, 2018-2030 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA CEPHALOSPORIN DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA CEPHALOSPORIN DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 108. DENMARK CEPHALOSPORIN DRUGS MARKET SIZE, BY GENERATION OF CEPHALOSPORIN, 2018-2030 (USD MILLION)
  • TABLE 109. DENMARK CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 110. DENMARK CEPHALOSPORIN DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 111. DENMARK CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 112. EGYPT CEPHALOSPORIN DRUGS MARKET SIZE, BY GENERATION OF CEPHALOSPORIN, 2018-2030 (USD MILLION)
  • TABLE 113. EGYPT CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 114. EGYPT CEPHALOSPORIN DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. EGYPT CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 116. FINLAND CEPHALOSPORIN DRUGS MARKET SIZE, BY GENERATION OF CEPHALOSPORIN, 2018-2030 (USD MILLION)
  • TABLE 117. FINLAND CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 118. FINLAND CEPHALOSPORIN DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. FINLAND CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 120. FRANCE CEPHALOSPORIN DRUGS MARKET SIZE, BY GENERATION OF CEPHALOSPORIN, 2018-2030 (USD MILLION)
  • TABLE 121. FRANCE CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 122. FRANCE CEPHALOSPORIN DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 123. FRANCE CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 124. GERMANY CEPHALOSPORIN DRUGS MARKET SIZE, BY GENERATION OF CEPHALOSPORIN, 2018-2030 (USD MILLION)
  • TABLE 125. GERMANY CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 126. GERMANY CEPHALOSPORIN DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 127. GERMANY CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 128. ISRAEL CEPHALOSPORIN DRUGS MARKET SIZE, BY GENERATION OF CEPHALOSPORIN, 2018-2030 (USD MILLION)
  • TABLE 129. ISRAEL CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 130. ISRAEL CEPHALOSPORIN DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. ISRAEL CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 132. ITALY CEPHALOSPORIN DRUGS MARKET SIZE, BY GENERATION OF CEPHALOSPORIN, 2018-2030 (USD MILLION)
  • TABLE 133. ITALY CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 134. ITALY CEPHALOSPORIN DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 135. ITALY CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 136. NETHERLANDS CEPHALOSPORIN DRUGS MARKET SIZE, BY GENERATION OF CEPHALOSPORIN, 2018-2030 (USD MILLION)
  • TABLE 137. NETHERLANDS CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 138. NETHERLANDS CEPHALOSPORIN DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. NETHERLANDS CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 140. NIGERIA CEPHALOSPORIN DRUGS MARKET SIZE, BY GENERATION OF CEPHALOSPORIN, 2018-2030 (USD MILLION)
  • TABLE 141. NIGERIA CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 142. NIGERIA CEPHALOSPORIN DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. NIGERIA CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 144. NORWAY CEPHALOSPORIN DRUGS MARKET SIZE, BY GENERATION OF CEPHALOSPORIN, 2018-2030 (USD MILLION)
  • TABLE 145. NORWAY CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 146. NORWAY CEPHALOSPORIN DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 147. NORWAY CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 148. POLAND CEPHALOSPORIN DRUGS MARKET SIZE, BY GENERATION OF CEPHALOSPORIN, 2018-2030 (USD MILLION)
  • TABLE 149. POLAND CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 150. POLAND CEPHALOSPORIN DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 151. POLAND CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 152. QATAR CEPHALOSPORIN DRUGS MARKET SIZE, BY GENERATION OF CEPHALOSPORIN, 2018-2030 (USD MILLION)
  • TABLE 153. QATAR CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 154. QATAR CEPHALOSPORIN DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 155. QATAR CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 156. RUSSIA CEPHALOSPORIN DRUGS MARKET SIZE, BY GENERATION OF CEPHALOSPORIN, 2018-2030 (USD MILLION)
  • TABLE 157. RUSSIA CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 158. RUSSIA CEPHALOSPORIN DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 159. RUSSIA CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 160. SAUDI ARABIA CEPHALOSPORIN DRUGS MARKET SIZE, BY GENERATION OF CEPHALOSPORIN, 2018-2030 (USD MILLION)
  • TABLE 161. SAUDI ARABIA CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 162. SAUDI ARABIA CEPHALOSPORIN DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 163. SAUDI ARABIA CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 164. SOUTH AFRICA CEPHALOSPORIN DRUGS MARKET SIZE, BY GENERATION OF CEPHALOSPORIN, 2018-2030 (USD MILLION)
  • TABLE 165. SOUTH AFRICA CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 166. SOUTH AFRICA CEPHALOSPORIN DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 167. SOUTH AFRICA CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 168. SPAIN CEPHALOSPORIN DRUGS MARKET SIZE, BY GENERATION OF CEPHALOSPORIN, 2018-2030 (USD MILLION)
  • TABLE 169. SPAIN CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 170. SPAIN CEPHALOSPORIN DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 171. SPAIN CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 172. SWEDEN CEPHALOSPORIN DRUGS MARKET SIZE, BY GENERATION OF CEPHALOSPORIN, 2018-2030 (USD MILLION)
  • TABLE 173. SWEDEN CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 174. SWEDEN CEPHALOSPORIN DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 175. SWEDEN CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 176. SWITZERLAND CEPHALOSPORIN DRUGS MARKET SIZE, BY GENERATION OF CEPHALOSPORIN, 2018-2030 (USD MILLION)
  • TABLE 177. SWITZERLAND CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 178. SWITZERLAND CEPHALOSPORIN DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 179. SWITZERLAND CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 180. TURKEY CEPHALOSPORIN DRUGS MARKET SIZE, BY GENERATION OF CEPHALOSPORIN, 2018-2030 (USD MILLION)
  • TABLE 181. TURKEY CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 182. TURKEY CEPHALOSPORIN DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 183. TURKEY CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 184. UNITED ARAB EMIRATES CEPHALOSPORIN DRUGS MARKET SIZE, BY GENERATION OF CEPHALOSPORIN, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED ARAB EMIRATES CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED ARAB EMIRATES CEPHALOSPORIN DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED ARAB EMIRATES CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED KINGDOM CEPHALOSPORIN DRUGS MARKET SIZE, BY GENERATION OF CEPHALOSPORIN, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED KINGDOM CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 190. UNITED KINGDOM CEPHALOSPORIN DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 191. UNITED KINGDOM CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 192. CEPHALOSPORIN DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 193. CEPHALOSPORIN DRUGS MARKET, FPNV POSITIONING MATRIX, 2023